SCHEMBL14634923

SCHEMBL14634923

Nc1ncnn2c(-c3ccncc3)cc(C(=O)NCCCCNC(=O)O)c12

nearest known ligand 0.80

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
CSNK2A2 P19784 20/20 0.80
CSNK2A1 P68400 20/20 0.80

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14634927 0.98 CSNK2A2 (0.83) CSNK2A2CSNK2A1
SCHEMBL2558402 0.92 CSNK2A2 (0.80) CSNK2A2CSNK2A1
SCHEMBL14635010 0.91 CSNK2A2 (0.79) CSNK2A2CSNK2A1
SCHEMBL2561736 0.91 CSNK2A2 (0.81) CSNK2A2CSNK2A1
SCHEMBL2546150 0.91 CSNK2A2 (0.81) CSNK2A2CSNK2A1
SCHEMBL14635504 0.89 CSNK2A2 (1.00) CSNK2A2CSNK2A1
SCHEMBL14634922 0.87 CSNK2A2 (0.75) CSNK2A2CSNK2A1
SCHEMBL14635394 0.87 CSNK2A2 (0.77) CSNK2A2CSNK2A1
SCHEMBL14634956 0.85 CSNK2A2 (0.73) CSNK2A2CSNK2A1
SCHEMBL14635642 0.84 CSNK2A2 (0.74) CSNK2A2CSNK2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8791257-B2 Substituted pyrrolotriazines as protein kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-07-29 US disclosed
US-20130023514-A1 SUBSTITUTED PYRROLOTRIAZINES AS PROTEIN KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2013-01-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130023514-A1 SUBSTITUTED PYRROLOTRIAZINES AS PROTEIN KINASE INHIBITORS STK25, MAP3K15, MAP3K5 CSNK2A2 123/4885CSNK2A1 84/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.